Consensus Catalyst Pharmaceuticals, Inc.

Stocks

CPRX

US14888U1016

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 10/07/2026 +04			5-day change	1st Jan Change
31.47 ^USD	0.00%		+0.06%	+34.83%

07-10	Solaris Energy Infrastructure to Join S&P SmallCap 600	MT
07-09	Catalyst Pharmaceuticals, Inc. Announces Board Changes	CI

Evolution of the Average Target: Catalyst Pharmaceuticals, Inc.

Evolution of the Target Price: Catalyst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Catalyst Pharmaceuticals, Inc.

ce0d0d1999.KXAjs3On4Exfzm62de06NB5varO_QaXCGNJkkXEH1Rk.XUAU_hKKuSUFuTiHN4F0dVVbKYP4dZykV6Iv4Fw_5FJvCBbHIuXRIQaJHQ~ff8da1d36f66198a719a890cec3b87a6

Analysts' recommendations: Catalyst Pharmaceuticals, Inc.

05-07	Oppenheimer Downgrades Catalyst Pharmaceuticals to Market Perform From Outperform	MT
01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
07/08/25	Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance	RE
21/04/25	BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33	MT
28/02/25	Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating	MT
04/02/25	Baird Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $28 Price Target	MT
11/11/24	Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $36 From $30, Maintains Buy Rating	MT
09/08/24	Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating	MT
10/05/24	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating	MT
14/03/24	Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target	MT
07/03/24	BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23	MT
01/03/24	Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating	MT
21/12/23	Oppenheimer Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $30 Price Target	MT
20/06/23	Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $24 From $22, Maintains Buy Rating	MT
19/01/23	Truist Securities Adjusts Catalyst Pharmaceuticals' Price Target to $22 From $18, Keeps Buy Rating	MT
21/12/22	Truist Securities Adjusts Price Target on Catalyst Pharmaceuticals to $18 From $17, Maintains Buy Rating	MT
21/12/22	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $24 From $18, Keeps Buy Rating	MT
20/12/22	Piper Sandler Adjusts Catalyst Pharmaceuticals Price Target to $20 From $18, Maintains Overweight Rating	MT
24/08/22	Analyst recommendations: Intuit, XPeng, Rio Tinto, Prologis, Charter Communications...
24/08/22	Roth Capital Downgrades Catalyst Pharmaceuticals to Neutral From Buy; Price Target is $15.50	MT
11/08/22	Truist Securities Adjusts Catalyst Pharmaceuticals Price Target to $17 From $12, Maintains Buy Rating	MT
11/08/22	Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $18 From $15, Maintains Overweight Rating	MT
11/08/22	HC Wainwright Raises Catalyst Pharmaceuticals' Price Target to $18 From $12, Keeps Buy Rating	MT
11/08/22	Piper Sandler Adjusts Price Target on Catalyst Pharmaceuticals to $16 From $9, Reiterates Overweight Rating	MT
08/02/22	HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $12 From $9, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CATALYST PHARMACEUTICALS, INC.					+0.62%
	REGENERON PHARMACEUTICALS, INC.					+23.14%
	UCB					+15.18%
	CSL LIMITED					+10.89%
	SAMSUNG BIOLOGICS CO.,LTD.					+54.88%
	MODERNA, INC.					-37.44%
	BIOGEN INC.					+12.03%
	INCYTE CORPORATION					-5.96%
	INNOVENT BIOLOGICS, INC.					+35.21%
	BRIDGEBIO PHARMA, INC.					+13.64%
	Average					+12.22%
	Weighted average by Cap.					+15.43%